Rivaksan-Innovation of the Year at the 2021 Eurasian Summit

State Enterprise “AKADEMFARM” 12-13.10.2021 took part in EURASIAN PHARMACEUTICAL SUMMIT 2021 (Tashkent, Uzbekistan), as part of the implementation of the “Enterprise DEVELOPMENT PLAN for 2021-2025”, approved by the National Academy of Sciences of Belarus in 2020.

The Summit discussed trends in the development of pharmaceutical markets, peculiarities of drug registration in 13 countries: Russia, Kazakhstan, Uzbekistan, Kyrgyzstan, Belarus, Armenia, Azerbaijan, Tajikistan, Turkmenistan, Ukraine, Georgia, Moldova and Mongolia.

Within the framework of the Eurasian Pharmaceutical Summit, a competition was held for the Eurasian Pharma Awards in 16 nominations.

    State Enterprise “ACADEMPHARM” won in the nomination “INNOVATION OF THE YEAR” for the timeliness and innovation of its developments

The company received an award for launching the first generic drug of rivaroxaban, Rivaksan, on the Belarusian market. The drug is intended for the prevention and treatment of complications of cardiovascular diseases associated with an increased risk of blood clots.

This step will allow the State Enterprise “ACADEMPHARM” to increase the competitiveness of the enterprise in the markets of the EurAsEC countries.